--- title: "Weekly Recap | Hims & Hers Health +1.74%, lawsuits and insider selling alongside" type: "News" locale: "en" url: "https://longbridge.com/en/news/299511801.md" description: "Hims & Hers Health (HIMS) rose 1.74% over the week to close at $27.99, outperforming the S&P 500, which slipped 0.08%, by roughly 1.82 percentage points. The five days were choppy. Monday opened at $27.38 and surged to an intraday high of $29.44 before settling at $28.81, the clearest up day of the week. Tuesday through Thursday drifted lower into the $27.85-$28.00 area, and Friday finished at $27.99. The weekly range was 8.4%, and average daily volume came in at about 9." datetime: "2026-09-19T06:11:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/299511801.md) - [en](https://longbridge.com/en/news/299511801.md) - [zh-HK](https://longbridge.com/zh-HK/news/299511801.md) generator: "portal-rs" --- # Weekly Recap | Hims & Hers Health +1.74%, lawsuits and insider selling alongside ## The Week Hims & Hers Health (HIMS) rose 1.74% over the week to close at $27.99, outperforming the S&P 500, which slipped 0.08%, by roughly 1.82 percentage points. The five days were choppy. Monday opened at $27.38 and surged to an intraday high of $29.44 before settling at $28.81, the clearest up day of the week. Tuesday through Thursday drifted lower into the $27.85-$28.00 area, and Friday finished at $27.99. The weekly range was 8.4%, and average daily volume came in at about 9.03 million shares, roughly 24% below the median of the prior 60 sessions. ## Key Events The week was dominated by legal and regulatory headlines. Several firms circulated notices inviting shareholders to lead a securities fraud class action tied to the company’s health data sharing practices, with some reports linking the trigger to an FTC privacy lawsuit. On 18 September, the stock was reported up intraday, but a same-day filing disclosed that CTO Mohamed Elshenawy sold 7,954 shares worth about $225,400. There was also a technical piece flagging a historic chart signal for bulls, consistent with the stock trading near the upper end of its 60-day range. No company-specific product, earnings, or partnership news landed this week; attention stayed on shareholder litigation and insider selling. ## Analyst Ratings Among 17 covering institutions, 1 rates it buy, 2 rate it overweight, 13 rate it hold, and 1 has no opinion; none rate it underweight or sell. The consensus rating is hold, with a consensus target price of $31.29, about 11.8% above the latest close. Targets range from $23.00 to $42.00, a wide band that points to meaningful disagreement about fair value. In healthcare services, HIMS ranks 7th out of 53 companies in the industry rating ranking. ## The Week Ahead A run of U.S. macro data is due next week. The Richmond Fed composite index lands on Tuesday 22 September, EIA weekly crude and Cushing inventories on Wednesday 23 September, and on Thursday 24 September initial jobless claims, the current account balance, new home sales, and EIA natural gas storage all arrive together. Initial claims printed 196 previously; new home sales came in at 0.607 with a forecast of 0.608. For HIMS, the more relevant watch items are the cadence of privacy-suit follow-up statements and whether insider selling continues. ## In Short The stock edged higher and beat the market, but the narrative tilted toward legal risk and insider selling. The analyst picture is mixed: most of the 17 institutions stay at hold, and the consensus target implies modest upside, yet the $23 to $42 spread shows that view is far from uniform. Valuation is negative on earnings, price sits above the 20-day and below the 60-day average, and the latest session’s large-lot flow was net buying, though these signals come from different timeframes. Next week’s macro prints and any fresh litigation developments will test whether the week’s resilience holds. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md) - [HIMZ.US](https://longbridge.com/en/quote/HIMZ.US.md) - [HIYY.US](https://longbridge.com/en/quote/HIYY.US.md) ## Related News & Research - [Hims & Hers CFO Oluyemi Okupe sells 29,277 common shares for $876,846.15](https://longbridge.com/en/news/299939486.md) - [HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder](https://longbridge.com/en/news/293791898.md) - [Hims & Hers Health (HIMS) Is Up 13.8% After FTC Suit And AI Weight-Loss Launch - Has The Bull Case Changed?](https://longbridge.com/en/news/295313745.md) - [Hims & Hers CTO Mohamed Elshenawy sells 7,954 shares worth $225,421.06](https://longbridge.com/en/news/299360969.md) - [J.P. Morgan Assigns Hims & Hers Stock a 'Hold' Rating. What's Behind the Cautious Stance?](https://longbridge.com/en/news/298771060.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**